new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Merck Sharp x26 Dohme Corp
Merck Sharp x26 Dohme Corporation
Merck Sharp x26 Dohme Corp A Corporation A Subsidiary Of Merck x26 Co Inc
Merck Sharp x26 Dohme Corp And Northwestern University
Merck Sharp x26 Dohme Corp_20131212
Merck Sharp x26 Dohme Corp Institute De Recherche Pierre Fabre

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

  

Merck Sharp & Dohme Corp patents


      
Recent patent applications related to Merck Sharp & Dohme Corp. Merck Sharp & Dohme Corp is listed as an Agent/Assignee. Note: Merck Sharp & Dohme Corp may have other listings under different names/spellings. We're not affiliated with Merck Sharp & Dohme Corp, we're just tracking patents.

ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "M" | Merck Sharp & Dohme Corp-related inventors




Count Application # Date Merck Sharp & Dohme Corp patents (updated weekly) - BOOKMARK this page
12015008650503/26/15 Mono- and di-peg il-10 production; and uses
22015001159001/08/15 Dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
32012025303210/04/12 Novel cationic lipids with short lipid chains for oligonucleotide delivery
42012020281908/09/12 Combination therapy using a beta 3 adrenergic receptor agonists and an antimuscarinic agent
52016014389505/26/16  new patent  Heterocyclic compounds and methods of use thereof for the treatment of hepatitis c
62016014525505/26/16  new patent  Non-nucleoside reverse transcriptase inhibitors
72016014527205/26/16  new patent  Triazolo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
82016013617205/19/16 Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
92016013762205/19/16 Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
102016013025905/12/16 Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
112016013027305/12/16 Process for making cgrp receptor antagonists
122016013032705/12/16 Cmv neutralizing antigen binding proteins
132016013057405/12/16 Methods of measuring gene expression in facs-sorted cells
142016013065905/12/16 Compositions and methods for treating cancer
152016012235005/05/16 Process for the preparation of chiral tert-butyl 4-((1r,2s,5r)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamido)piperidine-1-carboxylate derivatives and (2s,5r)-7-oxo-n-piperidin-4-yl-6-(sulfoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
162016012238005/05/16 Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
172016011391004/28/16 Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
182016011400004/28/16 Co-agonists of the glucagon and glp-1 receptors
192016010683504/21/16 Combination therapies for cancer
202016010804804/21/16 Imidazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
212016010805904/21/16 Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
222016010207304/14/16 2-hydroxymethyl-substituted orexin receptor antagonists
232016009685804/07/16 Selective glycosidase inhibitors and uses thereof
242016008200503/24/16 Process of making and using pharmaceutical formulations of antineoplastic agents
252016008376503/24/16 Method for preparing antibodies having improved properties
262016008483903/24/16 Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
272016008484803/24/16 Assay for determining endogenous levels of analyte in vivo
282016007450203/17/16 Recombinant subunit dengue virus vaccine
292016007564503/17/16 Amidation process
302016007565003/17/16 Crystalline polymorphic forms of an antidiabetic compound
312016007565603/17/16 Quinoline amide m1 receptor positive allosteric modulators
322016007568403/17/16 Alpha 7 nicotinic acetylcholine receptor modulators and uses thereof-iii
332016007572403/17/16 Cetp inhibitors
342016006851003/10/16 Hydroxy-substituted orexin receptor antagonists
352016006851403/10/16 Halo and trifluoromethyl substituted orexin receptor antagonists
362016006853203/10/16 Novel compounds that are erk inhibitors
372016006859703/10/16 Fdf03 antibodies and uses thereof
382016006025503/03/16 Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
392016006025603/03/16 Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors
402016006027203/03/16 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
412016005325102/25/16 Immobilized ketoreductases and process for making and using immobilized ketoreductase
422016004552602/18/16 2'-disubstituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
432016004658102/18/16 Factor xia inhibitors
442016003981702/11/16 Triazolopyridyl compounds as aldosterone synthase inhibitors
452016004012402/11/16 Adapted lepidopteran insect cells for the production of recombinant proteins
462016004020102/11/16 Biocatalytic transamination process
472016004025202/11/16 Methods and compositions for treating cancer
482016004377402/11/16 C6-azaspiro iminothiadiazine dioxides as bace inhibitors, compositions, and their use
492016003188202/04/16 Imidazopyridyl compounds as aldosterone synthase inhibitors
502016002409101/28/16 Inhibitors of the renal outer medullary potassium channel
512016002410001/28/16 Process for preparing chiral dipeptidyl peptidase-iv inhibitors
522016001692101/21/16 S-imino-s-oxo-iminothiazine compounds as bace inhibitors, compositions, and their use
532016001692301/21/16 S-imino-s-oxo-iminothiadiazine compounds as bace inhibitors, compositions, and their use
542016001693501/21/16 2-pyridyloxy-4-ether orexin receptor antagonists
552016001694701/21/16 Substituted pyridizinone derivatives as pde10 inhibitors
562016001697501/21/16 C2-azaspiro iminothiazine dioxides as bace inhibitors, compositions, and their use
572016001703601/21/16 Cell line 3m
582016000836101/14/16 Compositions and methods for treating cancer
592016000968101/14/16 Compounds inhibiting leucine-rich repeat kinase enzyme activity
602016000968201/14/16 Compounds inhibiting leucine-rich repeat kinase enzyme activity
612016000968901/14/16 Compounds inhibiting leucine-rich repeat kinase enzyme activity
622016000969601/14/16 Compounds inhibiting leucine-rich repeat kinase enzyme activity
632016000072101/07/16 Gastro-retentive formulations
642016000092101/07/16 Ceftolozane antibiotic compositions
652016000222401/07/16 Novel indole derivatives useful as anti-diabetic agents
662016000225501/07/16 Antidiabetic bicyclic compounds
672016000225901/07/16 Inhibitors of the renal outer medullary potassium channel
682015037479512/31/15 O-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
692015037624912/31/15 Methods for increasing n-glycan occupancy and reducing production of hybrid n-glycans in pichia pastoris strains lacking alg3 expression
702015036824612/24/15 Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
712015036824712/24/15 2,6,7 substituted purines as hdm2 inhibitors
722015036826512/24/15 Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
732015036826912/24/15 Factor ixa inhibitors
742015036834412/24/15 Mdl-1 ligand
752015036868212/24/15 Immobilized transaminases and process for making and using immobilized transaminase
762015035979312/17/15 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
772015036109812/17/15 Heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
782015036110112/17/15 Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
792015035349812/10/15 Substituted isoquinolines as crth2 receptor modulators
802015035351612/10/15 Iminothiadiazine dioxides containing a thioamide, amidine, or amide oxime group as bace inhibitors, compositions, and their use
812015035353512/10/15 Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors
822015035355212/10/15 Purine inhibitors of human phosphatidylinositol 3-kinase delta
832015035355312/10/15 2,6,7,8 substituted purines as hdm2 inhibitors
842015035356512/10/15 Btk inhibitors
852015035357012/10/15 Btk inhibitors
862015035518412/10/15 Antibodies that bind to human programmed death ligand 1 (pd-l1)
872015034293112/03/15 Spirocyclic cetp inhibitors
882015034315312/03/15 Dual chamber mixing syringes and methods of using same
892015034315712/03/15 Medication injector with near-empty alert
902015034448712/03/15 Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
912015034450012/03/15 C2,c6 oxacyclic-fused thiazine dioxide compounds as bace inhibitors, compositions, and their use
922015033564811/26/15 Heterocycle-substituted tetracyclic compounds and methods of use thereof for the treatment of viral diseases
932015033694611/26/15 Novel 2-pyridinecarboxamide derivatives, compositions containing such compounds, and methods of treatment
942015033694811/26/15 Isotopically labeled biaryl urea compounds
952015033699111/26/15 Novel glucokinase activator compounds, compositions containing such compounds, and methods of treatment
962015033701311/26/15 Novel antibacterial agents for the treatment of gram positive infections
972015033727411/26/15 Pmt2-, och1-, pmt5- mutant cells
982015032952111/19/15 Process for making reverse transcriptase inhibitors
992015032953111/19/15 Amino-pyrimidine-containing spleen tyrosine kinase (syk) inhibitors
1002015032953911/19/15 4-pyridinonetriazine derivatives as hiv integrase inhibitors
1012015032954811/19/15 Substituted pyrrolopyrimidines as hdm2 inhibitors
1022015032955711/19/15 Inhibitors of the renal outer medullary potassium channel
1032015032956211/19/15 Factor ixa inhibitors
1042015032961211/19/15 Process for purifying insulin and analogues thereof
1052015032962811/19/15 Liquid formulations for an anti-tnf alpha antibody
1062015032963211/19/15 Solution formulations of engineered anti-il-23p19 antibodies
1072015032072411/12/15 Methods of treating diabetes by administering a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor
1082015032073311/12/15 Indazole compounds as aldosterone synthase inhibitors
1092015032086011/12/15 Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
1102015032203911/12/15 2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists
1112015032204011/12/15 3-ester-4 substituted orexin receptor antagonists
1122015032204111/12/15 2-pyridyloxy-4-nitrile-4-substituted orexin receptor antagonists
1132015032205611/12/15 Factor ixa inhibitors
1142015032207411/12/15 4-fluoropiperidine orexin receptor antagonists
1152015032251911/12/15 Biomarkers for psoriasis treatment response
1162015031522111/05/15 Nucleoside kinase bypass compositions and methods
1172015031392611/05/15 Syn3 compositions and methods
1182015031514111/05/15 Thrombin inhibitors
1192015031522111/05/15 Nucleoside kinase bypass compositions and methods
1202015031522611/05/15 Disulfide masked prodrug compositions and methods
1212015030609110/29/15 Aldosterone synthase inhibitors
1222015030746410/29/15 Therapeutic thiazolidinone compounds
1232015030746510/29/15 Iminothiadiazine dioxide compounds as bace inhibitors, compositions and their use
1242015030747910/29/15 Cyclobutyl benzimidazoles as pde 10 inhibitors
1252015030748810/29/15 Cyclopropyl imidazopyridine pde10 inhibitors
1262015030748910/29/15 Pyrimidine pde10 inhibitors
1272015030753310/29/15 Spirocyclic sulfones as gamma secretase inhibitors
1282015030758010/29/15 Oxyntomodulin analogs
1292015030759110/29/15 On-column refolding and purifying of lipoproteins
1302015030760610/29/15 Lyophilized spherical pellets of anti-il-23 antibodies
1312015030785010/29/15 Conditional replicating viral vectors
1322015029919810/22/15 Inhibitors of the renal outer medullary potassium channel
1332015029964810/22/15 Improved cultivation media and process for improved protein production by pichia strains
1342015029756610/22/15 Rorgammat inhibitors
1352015029912210/22/15 Glycosidase inhibitors and uses thereof
1362015029912510/22/15 Prodrug bipyridylaminopyridines as syk inhibitors
1372015029916710/22/15 Regioselective n-2 arylation of indazoles
1382015029919810/22/15 Inhibitors of the renal outer medullary potassium channel
1392015029922410/22/15 Inhibitors of irak4 activity
1402015029922710/22/15 Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders
1412015029924310/22/15 2'-alkynyl substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
1422015029964810/22/15 Improved cultivation media and process for improved protein production by pichia strains
1432015029969010/22/15 Engineered lower eukaryotic host strains deficient in grr1 activity for recombinant protein
1442015029013510/15/15 Process for making agglomerates using acoustic mixing technology
1452015029032510/15/15 Liquid formulations for tnfr:fc fusion proteins
1462015029155810/15/15 2-pyridyloxy-3-substituted-4-nitrile orexin receptor antagonists
1472015029156110/15/15 Substituted pyridone derivatives as pde10 inhibitors
1482015029162010/15/15 Glycosidase inhibitors and uses thereof
1492015029168310/15/15 Modified apol1 polypeptides
1502015028436810/08/15 Secondary alcohol substituted triazoles as pde10 inhibitors
1512015028437610/08/15 Mineralocorticoid receptor antagonists
1522015028437910/08/15 Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions and their use
1532015028438110/08/15 Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors
1542015028438910/08/15 N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels
1552015028441110/08/15 Novel azabenzimidazole hexahydrofuro[e,2-b]furan derivatives
1562015028475310/08/15 Process for the preparation of an intermediate for an orexin receptor antagonists
1572015027465610/01/15 Glycosidase inhibitors and uses thereof
1582015027466410/01/15 Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
1592015027467210/01/15 Substituted spiropiperidinyl compounds useful as gpr120 agonists
1602015027470810/01/15 Inhibitors of irak4 activity
1612015027471610/01/15 Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions and their use
1622015027473910/01/15 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
1632015027475510/01/15 Compound diversification using late stage functionalization
1642015027476710/01/15 4'-substituted nucleoside reverse transcriptase inhibitors
1652015027522210/01/15 Crz1 mutant fungal cells
1662015026571509/24/15 Posaconazole intravenous solution formulations stabilized by substituted beta-cyclodextrin
1672015026689509/24/15 Novel compounds that are erk inhibitors
1682015026689709/24/15 Hcv ns3 protease inhibitors
1692015025807409/17/15 Novel compounds that are erk inhibitors
1702015026073109/17/15 Antibodies, kit and detecting amyloid beta oligomers
1712015025075909/10/15 Composition for inhibition of cathepsin k
1722015025203309/10/15 2-pyridyloxy-3-ester-4-nitrile orexin receptor antagonists
1732015025203409/10/15 Benzoxazolinone compounds with selective activity in voltage-gated sodium channels
1742015025334109/10/15 Quantification of tau in biological samples by immunoaffinity enrichment and mass spectrometry
1752015024690209/03/15 Substitued benzofuran compounds and methods of use thereof for the treatment of viral diseases
1762015024691709/03/15 Inhibitors of hepatitis c virus replication
1772015023986608/27/15 Triazolyl derivatives as syk inhibitors
1782015023242808/20/15 Substituted phenyl-spleen tyrosine kinase (syk) inhibitors
1792015023244708/20/15 Crystalline form of a reverse transcriptase inhibitor
1802015022536508/13/15 Indoline compounds as aldosterone synthase inhibitors
1812015022540208/13/15 Treating diabetes with dipeptidyl peptidase-iv inhibitors
1822015021809608/06/15 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof
1832015021809708/06/15 Glycosidase inhibitors and uses thereof
1842015021814708/06/15 Glycosidase inhibitors and uses thereof
1852015021814908/06/15 Novel benzimidazole tetrahydrofuran derivatives
1862015021816408/06/15 Substituted naphthyridinedione derivatives as hiv integrase inhibitors
1872015021816908/06/15 3-aminocycloalkyl compounds as rorgammat inhibitors and uses thereof
1882015020942407/30/15 Inactivated varicella zoster virus vaccines, methods of production, and uses thereof
1892015021068507/30/15 Novel azabenzimidazole tetrahydropyran derivatives
1902015021068707/30/15 N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof
1912015020348707/23/15 Novel azabenzimidazole tetrahydrofuran derivatives
1922015020349607/23/15 Aliphatic spirolactam cgrp receptor antagonists
1932015020351207/23/15 Macrocyclic compounds as hiv integrase inhibitors
1942015019749007/16/15 Crystalline polymorphic forms of an antidiabetic compound
1952015019753107/16/15 Sulfonamide derivatives and methods of use thereof for improving the pharmacokinetics of a drug
1962015019757007/16/15 Anti-ilt5 antibodies and ilt5-binding antibody fragments
1972015019777207/16/15 Mammalian expression vector puhab
1982015019040207/09/15 Solid dosage formulations of an orexin receptor antagonists
1992015019143407/09/15 3-cyclohexenyl and cyclohexyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
2002015019146107/09/15 Pyrazolyl derivatives as syk inhibitors
2012015019149507/09/15 Antidiabetic tricyclic compounds
2022015018250307/02/15 Mineralocorticoid receptor antagonists
2032015017553406/25/15 Alpha-7 nicotinic acetylcholine receptor modulators and uses therof-i
2042015017557506/25/15 Imidazolyl analogs as syk inhibitors
2052015017560906/25/15 Treating diabetes with dipeptidyl peptidase-iv inhibitors
2062015016648606/18/15 Substituted diazine and triazine spleen tyrosine kinease (syk) inhibitors
2072015016649006/18/15 Mineralocorticoid receptor antagonists
2082015016652006/18/15 Amido-substituted pyrimidinone derivatives useful for the treatment of hiv infection
2092015015893506/11/15 Protective vaccine based on staphylococcus aureus sa2493 protein
2102015015099006/04/15 Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas
2112015015212706/04/15 Permeable glycosidase inhibitors and uses thereof
2122015014733705/28/15 Crystalline anti-human il-23 antibodies
2132015014824605/28/15 Surface anchored light chain bait antibody display system
2142015014832705/28/15 Substituted pyridine spleen tyrosine kinase (syk) inhibitors
2152015013998605/21/15 Ilt3 binding molecules and uses therefor
2162015014142805/21/15 Trka kinase inhibitors, compositions and methods thereof
2172015014144405/21/15 N-methyl tetrahydroquinoline m1 receptor positive allosteric modulators
2182015012644305/07/15 Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
2192015012649305/07/15 Bicyclic sulfone compounds for inhibition of rorgamma activity and the treatment of disease
2202015011939404/30/15 Insulin-like growth factor-1 receptor inhibitors
2212015011186604/23/15 Cyclic amine substituted heterocyclic cetp inhibitors
2222015011187704/23/15 Tetrahydronaphthyridine and related bicyclic compounds for inhibition of rorgamma activity and the treatment of disease
2232015011191404/23/15 Spirolactam cgrp receptor antagonists
2242015010445304/16/15 Fdf03 antibodies and uses thereof
2252015010446504/16/15 Il-19 as a biomarker of tslp treatment
2262015010531704/16/15 Glucose-responsive insulin conjugates
2272015010535404/16/15 Heterocyclic aspartyl protease inhibitors
2282015009989104/09/15 Novel crystalline forms of a dipeptidyl peptidase-iv inhibitors
2292015009971504/09/15 Formulations of acadesine
2302015009971904/09/15 Cathepsin cysteine protease inhibitors
2312015009972904/09/15 Inhibitors of the renal outer medullary potassium channel
2322015009977104/09/15 Pyridine cgrp receptor antagonists
2332015009339804/02/15 Methods and compositions for treating or preventing cancer
2342015008390603/26/15 Biomarkers for monitoring intervention therapies for diabetes
2352015008764103/26/15 Heterocyclic cgrp receptor antagonists
2362015008783203/26/15 Process for making beta 3 agonists and intermediates
2372015007899603/19/15 Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
2382015007903103/19/15 Use of pegylated il-10 to treat cancer
2392015008059803/19/15 Asymmetric synthesis for preparing fluoroleucine alkyl esters
2402015006419203/05/15 Mammalian cell surface antigens; related reagents
2412015005619102/26/15 Igf1 biomarker for igf1r inhibitor therapy
2422015005122702/19/15 Predictive biomarker useful for cancer therapy mediated by a cdk inhibitor
2432015005124802/19/15 Imidazolyl methyl piperidine t-type calcium channel antagonists
2442015004425002/12/15 Vaccines against clostridium difficile comprising recombinant toxins
2452015004534602/12/15 Selective glycosidase inhibitors and uses thereof
2462015004557502/12/15 Process for preparing fluoroleucine alkyl esters
2472015003849002/05/15 Spiropyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease
2482015003849802/05/15 Thrombin inhibitors
2492015003850202/05/15 Isoxazolopyridine orexin receptor antagonists



ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Merck Sharp & Dohme Corp in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Merck Sharp & Dohme Corp with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###